COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,741 Articles (22,502 medRxiv, 8,239 bioRxiv)

Most recent first Previous |  Page 1532: Articles 15311-15320  | Next

Is large-scale rapid CoV-2 testing a substitute for lockdowns? The case of Tuebingen
Diederichs, M., Kremsner, P., Mitze, T., Schulz, F., Mueller, G. J., Papies, D., Waelde, K.
10.1101/2021.04.26.21256094 — Posted: 2021-04-26 Discussion: Onsite
Conserved in 186 countries the RBD fraction of SARS CoV-2 S-protein with in-silicoT500S mutation strongly blocks ACE2 rejecting the viral spike; A Molecular-docking analysis.
Banerjee, A., Kanwar, M., Santra, D., Maiti, S.
10.1101/2021.04.25.441361 — Posted: 2021-04-26
A Novel Evidence-Based Predictor Tool for Hospitalization and Length of Stay: Insights from COVID19 Patients in New York City
El Halabi, M., Feghali, J., Tallon de Lara, P., Narasimhan, B., Ho, K., Saabeyi, J., Huang, J., Osorio, G., Mathew, J., Wisnivesky, J., Steiger, D.
10.1101/2021.04.24.21256042 — Posted: 2021-04-26
Insertions in SARS-CoV-2 genome caused by template switch and duplications give rise to new variants of potential concern
Garushyants, S. K., Rogozin, I. B., Koonin, E. V.
10.1101/2021.04.23.441209 — Posted: 2021-04-26
Analysis of viral RNA-host protein interactomes enables rapid antiviral drug discovery
Zhang, S., Huang, W., Ren, L., Ju, X., Gong, M., Rao, J., Sun, L., Li, P., Ding, Q., Wang, J., Zhang, Q. C.
10.1101/2021.04.25.441316 — Posted: 2021-04-26
A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope
VanBlargan, L., Adams, L., Liu, Z., Chen, R. E., Gilchuk, P., Raju, S., Smith, B., Zhao, H., Case, J. B., Winkler, E. S., Whitener, B., Droit, L., Aziati, I., Shi, P.-Y., Creanga, A., Pegu, A., Handley, S., Wang, D., Boon, A., Crowe, J. E., Whelan, S. P. J., Fremont, D., Diamond, M.
10.1101/2021.04.26.441501 — Posted: 2021-04-26
A SARS CoV-2 nucleocapsid vaccine protects against distal viral dissemination
Class, J., Dangi, T., Richner, J., Penaloza-MacMaster, P.
10.1101/2021.04.26.440920 — Posted: 2021-04-26
Control-theoretic immune tradeoffs explain SARS-CoV-2 virulence and transmission variation
Sarma, A. A., Sarma, A., Csete, M., Lee, P. P., Doyle, J. C.
10.1101/2021.04.25.441372 — Posted: 2021-04-26
Production of a Highly Immunogenic Antigen from SARS-CoV-2 by Covalent Coupling of the Receptor Binding Domain of Spike Protein to a Multimeric Carrier
Argentinian AntiCovid Consortium, , Berguer, P. M., Blaustein, M., Bredeston, L., Craig, P. O., D'Alessio, C., Elias, F., Farre, P. C., Fernandez, N. B., Gentili, H. G., Gandola, Y., Gasulla, J., Gudesblat, G. E., Herrera, M. G., Ibanez, L. I., Idrovo-Hidalgo, T., Nadra, A. D., Noseda, D. G., Pavan, C. H., Pavan, M. F., Pignataro, M. F., Roman, E., Ruberto, L. A. M., Rubinstein, N., Sanchez, M. V., Santos, J., Wetzler, D. E., Zelada, A. M.
10.1101/2021.04.25.441271 — Posted: 2021-04-26
6-Month Follow Up of 8679 Hospitalized COVID-19 Patients in Germany: A Nationwide Cohort Study
Guenster, C., Busse, R., Spoden, M., Rombey, T., Schillinger, G., Hoffmann, W., Weber-Carstens, S., Schuppert, A., Karagiannidis, C.
10.1101/2021.04.24.21256029 — Posted: 2021-04-26 Discussion: Offsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).